Difference between revisions of "Unification of regulatory approval"
(One intermediate revision by the same user not shown) | |||
Line 2: | Line 2: | ||
==Description:== | ==Description:== | ||
Seeing the benefit and the effectiveness of the European Union, countries in different regions start forming | Seeing the benefit and the effectiveness of the European Union, countries in different regions start forming | ||
Line 42: | Line 41: | ||
Dates for key milestones in the development of the driving force. | Dates for key milestones in the development of the driving force. | ||
==Web Resources:== | ==Web Resources:== | ||
http://www.who.int/medicines/publications/pharmacopoeia/en/ |
Latest revision as of 19:41, 16 September 2009
This page is under construction and edited by Susan Liu EMBA09. In case of any questions/remarks, feel free to contact me
Description:
Seeing the benefit and the effectiveness of the European Union, countries in different regions start forming alliances and use common rules for regulations and policies. This can mean a unified regulations and approval process for pharmeceutical regulations.
In addition, the WHO is working closely with the WTO to put pressure on Afican countries and the IMF to ensure drugs can be delivered to the ones who need them. If they do not do so, aids and funds would be limited or even denied.
Enablers:
Political Alliances
Regional Development
WHO initiatives to distribute drugs worldwide for those in need
Inhibitors:
Political Chaos
De-globolization
Paradigms:
Changes in ways of thinking about the world due to the driving force.
Experts:
Martin D. Hynes--Pharmaceutical Pre-Approval Inspections: A Guide to Regulatory
The Generic Pharmaceutical Industry Association (GPIA)
National Pharmaceutical Alliance (NPA)
WHO
Timing:
Dates for key milestones in the development of the driving force.